Latest Clinical trials biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

by Ysios Capital

11 months ago
VMX-C001, anticoagulants, VarmX

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2...

Specifically designed diets demonstrate a 'powerful ability' to prevent tumorigenesis, delay tumor growth and improve existing cancer treatments, CNIO researchers say in a review paper

by CNIO - Centro Nacional de Investigaciones Oncológicas

11 months ago
Caloric restriction, ketogenic diet and intermittent fasting

The Growth Factors, Nutrients and Cancer group at the Spanish National Cancer Research Center (CNIO), led by Nabil Djouder, have now published a review on the use of diet in cancer treatment in Trends...

Un ensayo clínico determina la pauta óptima de revacunación contra la hepatitis B en pacientes con cirrosis

by Instituto de Biomedicina de Sevilla - IBIS

11 months ago
cirrosis, hepatitis B

Dos grupos de investigación del Instituto de Biomedicina de Sevilla (IBiS), y del Hospital Virgen del Rocío (HUVR), han consolidado la recomendación de revacunar frente a la hepatitis B a los pacie...

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

by Ysios Capital

11 months ago
X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD), CALYX, leriglitazone

Minoryx Therapeutics today announces the US Food and Drug Administration (FDA) approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukod...

Vita 34 inicia un nuevo ensayo clínico

by Secuvita

11 months ago
Tarcidomgen Kimleucel, CAR-T

Ha comenzado la inscripción en la Fase I del ensayo clínico Tarcidomgen Kimleucel. El candidato a fármaco es un CAR-T anti-CD19, un receptor de antígeno quimérico y el primer candidato en la cart...

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease

by 3P Biopharmaceuticals

11 months ago
FGF-1, 3P Biopharmaceuticals, Zhittya

3P Biopharmaceuticals and the American biotech company, Zhittya Genesis Medicine (Zhittya), have successfully accomplished the process transfer and GMP supply of FGF-1 candidate.

A preclinical trial shows the effectiveness of photodynamic therapy against glioblastoma

by Fundació Clínic per a la Recerca Biomèdica

11 months ago
photodynamic therapy, Glioblastoma, 5-aminolevulinic acid (5-ALA)

Researchers at IDIBAPS-Hospital Clínic Barcelona show that the administration of a light-sensitive drug reduces tumour viability in a three-dimensional model that simulates neural tissue and glioblas...

Un nuevo anticuerpo conjugado podría ser útil para personalizar el tratamiento de pacientes con cáncer epitelial de ovario recurrente que expresan la proteína FolRα

by Vall d’Hebron

11 months ago
(ADC) Luveltamab tazevibulin (luvelta), folato alfa (FolRα)

Los resultados del estudio fase I STRO-002 de expansión de dosis del fármaco luveltamab tazevibulin (luvelta) demuestran beneficios clínicos significativos en pacientes con cáncer de ovario con ex...

CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy

by VHIO

11 months ago
PD-(L)1 inhibitors, atezolizumab, cabozantinib

The data obtained in the study in which VHIO participated underline the importance of prospective evaluation of re-exposure to immunotherapy before it is adopted as a standard of care.

A novel treatment combination shows promise as first-line treatment in patients with metastatic castration-resistant prostate cancer

by VHIO

11 months ago
talazoparib, enzalutamida, Metastatic castration-resistant prostate cancer (mCRPC), TALAPRO-2

Results from the Phase III TALAPRO-2 trial demonstrate that the combination of talazoparib plus enzalutamide vs. standard treatment of enzalutamide plus placebo significantly improves progression-free...

Connecta Therapeutics starts clinical trials for its Fragile X syndrome drug

by Connecta Therapeutics

11 months ago
Connecta Therapeutics, CTH120, Fragile X syndrome (FXS)

Connecta Therapeutics, a clinical stage biotechnology company focusing on the development of new treatments for central nervous system (CNS) disorders without therapeutic options, has been granted ...

El Hospital 12 de Octubre participa en un ensayo clínico internacional que demuestra que una pastilla detiene varios años la progresión de un tumor cerebral maligno

by Hospital Universitario 12 de Octubre

11 months ago
Glioma Difuso grado 2, IDH, vorasidenib

El Hospital 12 de Octubre participa en un ensayo clínico internacional que demuestra que un inhibidor denominado vorasidenib, que se administra vía oral, detiene varios años la progresión de un ti...